logo
Rs 27,000 crore government securities auction fully subscribed

Rs 27,000 crore government securities auction fully subscribed

India Gazette23-05-2025
New Delhi [India], May 23 (ANI): Government securities (G-sec) auction of Rs. 27,000 crore bonds in two tranches on Friday was fully subscribed, reflecting strong investor demand. The cut-off price for both bonds was above par. The 6.75 per cent G-sec with a notified amount of Rs. 15,000 crore maturing in 2029 was sold at a cut-off price of Rs 103.49, yielding 5.8675 per cent. The 7.09 per cent G-sec with a notified amount of Rs 12,000 crore, maturing in 2054, was sold at a cut-off price of Rs 103.39, yielding 6.8197 per cent.
The bond yield is the return an investor expects to receive each year over its term to maturity.As per the auction results, the development of primary dealers was stated as 'NIL' for both thebonds, indicating healthy demand for G-sec from the investor community.
Primary Dealers, commonly referred to as PDs, are financial institutions authorized by the RBI to buy and sell government securities.
The underwriting auction was conducted through multiple price-based methods on May 23 (Friday) between 09:00 A.M. and 09:30 A.M.
Bids under Additional Competitive Underwriting (ACU) auction was done electronically through the Core Banking Solution (E-Kuber) System.
Earlier this year, on March 27, the government had notified the indicative calendar for theissuance of government-dated securities, including Sovereign Green Bonds (SGrBs), for thefirst half of the fiscal year 2025-26 (April 1, 2025, to September 30, 2025).
The indicative calendar for such auctions is released beforehand in order to enable institutional and retail investors to plan their investments efficiently and to provide transparency and stability to the Government Securities market. (ANI)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tech Park: Karnataka CM Siddaramaiah's meeting on Tuesday to decide on farmers offer to sell their land for Rs 3.5 cr per acre
Tech Park: Karnataka CM Siddaramaiah's meeting on Tuesday to decide on farmers offer to sell their land for Rs 3.5 cr per acre

Time of India

time39 minutes ago

  • Time of India

Tech Park: Karnataka CM Siddaramaiah's meeting on Tuesday to decide on farmers offer to sell their land for Rs 3.5 cr per acre

Protesting farmers from Devanahalli have offered to give up 449 acres near the international airport for the proposed high-tech park if the government fixes a rate of Rs 3.5 crore per acre . The state government will take a decision on the demand at July 15 meeting to be chaired by Chief Minister Siddaramaiah. Industries Minister MB Patil , speaking to the media on Sunday, said he hoped a solution would emerge on Tuesday. The farmers are demanding higher compensation, suitable jobs for locals who are giving up their lands and declaring the surrounding areas as a yellow zone. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Villas In Dubai | Search Ads Get Rates Patil said the government was keen to balance the interests of farmers with the need for industrialization. There are also demands from local protestors to preserve the agricultural lands, which has led to a thinking in the government to declare the region as a green zone. The government, the minister added, was aware not all protesters were genuine farmers and some of them have already entered into agreements with big builders agreeing to sell their lands for real estate. Live Events Farmers of Channarayapatna hobli in Bengaluru rural district have been on a protest seeking to stall the acquisition. The previous BJP regime had, on August 27, 2021, issued a preliminary notification proposing acquisition of 1,772.2 acres of land from 13 villages in Channarayapatna hobli. Patil, the industries minister, had said last month that the process of acquiring the remaining 1,232 acres of land will go on as planned before.

Cipla eyes entry into India's weight management market amid rising demand and global competition
Cipla eyes entry into India's weight management market amid rising demand and global competition

Economic Times

time40 minutes ago

  • Economic Times

Cipla eyes entry into India's weight management market amid rising demand and global competition

Synopsis Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also strengthening its central nervous system portfolio through strategic in-licensing deals and acquisitions, particularly in ADHD and Parkinson's disease. The company is also focusing on innovation-led solutions to combat antimicrobial resistance and aims to be a global, patient-centric healthcare leader. Agencies Representative image Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra has Mumbai-based firm is also strengthening its presence in the central nervous system (CNS) therapeutic area, he stated in his address to shareholders in the company's Annual Report for 2024-25."Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions," Vohra domestic drug firms are developing drugs for weight loss to capitalise on the growing market for obesity and diabetes drugmaker Eli Lilly & Co has already launched its anti-obesity drug Mounjaro in the country. Danish firm Novo Nordisk has also launched its anti-obesity drug Wegovy, indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular the CNS segment, Cipla has successfully in-licensed Sanofi's India CNS product range, including Frisium, a leading brand in the anti-epileptic category, Vohra informed shareholders."Building on this momentum, we aim to pursue similar in-licensing deals or acquisitions in niche indications of attention deficit hyperactivity disorder (ADHD) and Parkinson's disease," he company is equally committed to addressing the global crisis of antimicrobial resistance (AMR), he added."Our AMR portfolio is evolving from volume-based to innovation-led, with four novel products in development," Vohra noted that the company's ambition is to be a global, innovation-led, patient-centric healthcare company that creates long-term value through science, empathy, and sustainability."We will continue to invest in big brands, strategic alliances, digital infrastructure, and next-generation therapies, while remaining rooted in our founding values of care and compassion," Vohra stated. Cipla's consolidated revenue stood at Rs 27,548 crore in FY25. Its consolidated net profit rose to Rs 5,272 crore during the period.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store